| Name | Title | Contact Details |
|---|---|---|
Michael Mayes |
Executive Director, Anti-Bribery and Anti-Corruption, Third Party and Distributor Compliance Lead | Profile |
Novel therapeutics for metabolic and endocrine disorders
Lindus Health is a next generation CRO that helps biotech and healthtech pioneers run faster, more reliable clinical trials. They provide end-to-end clinical trial services, including trial design, recruitment, and delivery, and have a unique technolog...
We are a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire`s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications.
Founded in 1949, Stevanato Group is committed to create systems, processes and services that guarantee the integrity of parenteral medicines. It is comprised of two operational divisions: Pharmaceutical Systems (Ompi and Balda brands): specialized in ready-to-use glass containers and bulk primary packaging (syringes, cartridges, vials, and ampoules); high quality and high precision plastic solutions for diagnostic, pharmaceutical and medical device applications. Engineering Systems (Spami, Optrel, InnoScan and SVM brands): specialized in glass forming technology, inspection systems, assembly, packaging machines and serialization solutions for the pharmaceutical industry. These two divisions enjoy a close, synchronous relationship, featuring daily exchanges which ensure that Stevanato Group has complete control over the entire production process, from purchasing the finest raw materials to offering exceptional after-sales customer service. The Group also benefits from the SG Lab activity that provides technical and analytical services on the potential interaction between the pharmaceutical product and the container.
At Santen, we`re innovating therapies to improve the quality of life for patients worldwide. Our single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a global company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Our clinical development network now spans three continents, with centers in EMEA (Europe, the Middle East and Africa), Japan, and the United States.